Ketamine Study Points to a More Integrated Approach for Depression and Alcohol Use Disorder
A new study presented at ASAM 2026 adds to a growing question in mental health care: can one treatment help address both major depression and alcohol use disorder at the same time? The early answer is cautious, but meaningful. In adults with both conditions, ketamine appeared to offer longer lasting benefits for depression than an active placebo, while also showing signals of improvement in anxiety and quality of life.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
Key Takeaways
| Finding | What It Means |
|---|---|
| Study population | Adults with both major depressive disorder and alcohol use disorder |
| Treatment tested | IV ketamine, with or without injectable naltrexone |
| Comparator | Midazolam, an active placebo |
| Depression results | More than 80 percent of participants achieved depression remission across groups |
| Ketamine signal | Depression benefits lasted longer in the ketamine groups |
| Alcohol outcomes | Researchers did not find significant differences between groups |
| Safety | No study related serious adverse events were reported |
| Big picture | Ketamine may have value in complex patients, but more research is needed |
Why This Study Matters
Depression and alcohol use disorder often travel together. That pairing can make treatment harder. Depression may drive drinking. Drinking may deepen depression. Many patients end up moving between separate treatment plans, even when the two conditions are tightly connected.
That is what makes this study notable. Researchers looked at ketamine not only as a rapid acting depression treatment, but as a possible option for patients whose depression overlaps with alcohol misuse.
The trial included 65 adults with current major depressive disorder and alcohol use disorder. Participants received one of three regimens: ketamine plus naltrexone, ketamine plus saline, or midazolam plus saline. Ketamine was given once weekly for four weeks.
What Researchers Found
The most striking result was not that ketamine clearly beat the comparison group on every measure. It did not.
All three groups improved, and more than 80 percent of participants reached depression remission. Researchers did not find significant group differences in alcohol related outcomes.
Still, ketamine stood out in important ways. The antidepressant effects lasted longer in the ketamine groups compared with midazolam. The ketamine groups also showed greater improvement in anxiety and quality of life. Adding naltrexone did not appear to blunt ketamine’s therapeutic effect.
That matters because some researchers have questioned whether blocking opioid receptors might reduce ketamine’s antidepressant benefit.
What Patients Should Know
This study does not mean ketamine is now a proven treatment for alcohol use disorder. It also does not mean patients with substance use histories should seek ketamine without careful screening.
But it does suggest that clinics and researchers should not automatically exclude people with alcohol use disorder from ketamine research or care models.
For patients with depression and alcohol use disorder, the larger message is practical. The most useful treatments may be the ones that acknowledge how closely these conditions interact. Ketamine may become part of that conversation, especially when care is supervised, structured, and paired with broader addiction support.
